Monalizumab

Human IgG4 kappa

Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC₅₀ for this effect is 4.83 ng/mL.

Monalizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 28;16(1):865. [Abstract]

Customer Validation
Healthy donor PBMCs were co-cultured with SKO-007 (J3) target cells, either untreated or treated with the indicated inhibitors for 48 h. NK cell degranulation assay was conducted at an Effector/Target (E/T) ratio of 2.5:1 in complete medium at 37 °C and 5% CO₂ for 2 h. To assess the role of the NKG2A or KIR receptors, NK cells pretreated with blocking mAbs for NKG2A (Monalizumab,15 min) or IgG control were incubated with Pol I inhibitor-treated target cells.

Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]

Customer Validation
Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks). Body weights and tumor volumes were measured twice a week from the seventh day after injection of cancer cells.

Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]

Customer Validation
Plasma perforin concentrations were determined by ELISA. The results showed that Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks) treatment significantly increased perforin levels, which were lower in RT-R-MDA-MB-231-injected mice than in MDA-MB-231-injected mice.

Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]

Customer Validation
Degranulation of NKG2A⁺ KIR⁻ NK cells after 4 hours of co-culture with untreated or 12 hours IFNγ-pretreated WT or HLA-E KO A375 cells in the presence of 5 µg/mL IgG₁ or Monalizumab (mona) mAb (n=6).

Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]

Customer Validation
Reduction in B2M KO cell population after 24 hours of co-culture of NK cells with mixed WT:B2M KO cells (1:1) at different E:T ratios in the presence of 5 µg/mL of indicated mAbs (Monalizumab (mona), etc.).

Monalizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jan 8;42(1):135-156.e17. [Abstract]

Customer Validation
Flow cytometry panels demonstrating the expression level of NKG2A^⁺, PD-1^⁺Tim-3^⁺, Granzyme B^⁺ and IFN-γ^⁺ in CD8^⁺ tumor infiltrating T cells co-cultured with HLA-E^⁺ tumor infiltrating B cells, either treated without Monalizumab (upper panel) or with Monalizumab (100 mg/mL; 20 h) (bottom panel).